Comprehensive outcomes after lung retransplantation: A single‐center review
Introduction Lung retransplantation is an important therapy for a growing population of lung transplant recipients with graft failure, but detailed outcome data are lacking. Methods We conducted a retrospective cohort study of adult lung retransplant in the Toronto Lung Transplant Program from 2001...
Gespeichert in:
| Veröffentlicht in: | Clinical transplantation 2018-06, Vol.32 (6), p.e13281-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 6 |
| container_start_page | e13281 |
| container_title | Clinical transplantation |
| container_volume | 32 |
| creator | Halloran, Kieran Aversa, Meghan Tinckam, Kathryn Martinu, Tereza Binnie, Matthew Chaparro, Cecilia Chow, Chung‐Wai Waddell, Tom McRae, Karen Pierre, Andrew Perrot, Marc Yasufuku, Kazuhiro Cypel, Marcelo Keshavjee, Shaf Singer, Lianne G. |
| description | Introduction
Lung retransplantation is an important therapy for a growing population of lung transplant recipients with graft failure, but detailed outcome data are lacking.
Methods
We conducted a retrospective cohort study of adult lung retransplant in the Toronto Lung Transplant Program from 2001 to 2013 (n = 38). We analyzed the postoperative course, graft function, renal function, microbiology, donor‐specific antibodies (DSA), quality of life, and survival compared to a control cohort of primary transplant recipients matched for age and era.
Results
Indication for retransplant was chronic lung allograft dysfunction in most retransplant recipients (35/38, 92%). The postoperative course was more complex after retransplant than primary (ventilation time, 8 vs 2 days, P |
| doi_str_mv | 10.1111/ctr.13281 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2038705665</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2038705665</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3251-378a91d3c4674a95df9a7e9706aa45e201f165e8e58a795dc17314cb7f154eb03</originalsourceid><addsrcrecordid>eNp1kEtOwzAQhi0EoqWw4AIoS1iktePYjtlVES-pCAmVteW6kxKUF3bSqjuOwBk5CS4p7JjNjGY-fRr9CJ0TPCa-Jqa1Y0KjhBygIaFShhiT6BANscSRnzkdoBPn3vyWE86O0SCSgsUxSYboMa3LxsIrVC5fQ1B3ralLcIHOWrBB0VWrwEJrdeWaQletbvO6ug6mgcurVQFfH58Gqh1pYZ3D5hQdZbpwcLbvI_RyezNP78PZ091DOp2FhkaMhFQkWpIlNTEXsZZsmUktQArMtY4ZRJhk_k9IgCVa-LMhgpLYLERGWAwLTEfosvc2tn7vwLWqzJ2Bwr8IdedUhGkiMOOcefSqR42tnbOQqcbmpbZbRbDapad8euonPc9e7LXdooTlH_kblwcmPbDJC9j-b1Lp_LlXfgODhnpI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2038705665</pqid></control><display><type>article</type><title>Comprehensive outcomes after lung retransplantation: A single‐center review</title><source>Access via Wiley Online Library</source><creator>Halloran, Kieran ; Aversa, Meghan ; Tinckam, Kathryn ; Martinu, Tereza ; Binnie, Matthew ; Chaparro, Cecilia ; Chow, Chung‐Wai ; Waddell, Tom ; McRae, Karen ; Pierre, Andrew ; Perrot, Marc ; Yasufuku, Kazuhiro ; Cypel, Marcelo ; Keshavjee, Shaf ; Singer, Lianne G.</creator><creatorcontrib>Halloran, Kieran ; Aversa, Meghan ; Tinckam, Kathryn ; Martinu, Tereza ; Binnie, Matthew ; Chaparro, Cecilia ; Chow, Chung‐Wai ; Waddell, Tom ; McRae, Karen ; Pierre, Andrew ; Perrot, Marc ; Yasufuku, Kazuhiro ; Cypel, Marcelo ; Keshavjee, Shaf ; Singer, Lianne G.</creatorcontrib><description>Introduction
Lung retransplantation is an important therapy for a growing population of lung transplant recipients with graft failure, but detailed outcome data are lacking.
Methods
We conducted a retrospective cohort study of adult lung retransplant in the Toronto Lung Transplant Program from 2001 to 2013 (n = 38). We analyzed the postoperative course, graft function, renal function, microbiology, donor‐specific antibodies (DSA), quality of life, and survival compared to a control cohort of primary transplant recipients matched for age and era.
Results
Indication for retransplant was chronic lung allograft dysfunction in most retransplant recipients (35/38, 92%). The postoperative course was more complex after retransplant than primary (ventilation time, 8 vs 2 days, P < .01; ICU stay 14 vs 4 days, P < 0.01), and peak lung function was lower (FEV1 2.2L vs 3L, P < .01). Quality of life scores were comparable, as were renal function, microbiology, and donor‐specific antibody formation. Median survival was 1988 days after primary and 1475 days after retransplant (P = .39).
Conclusions
Lung retransplantation is associated with a more complex postoperative course and lower peak lung function, but the long‐term medical profile is similar to primary transplant. Lung retransplantation can be beneficial for carefully selected candidates with allograft failure.</description><identifier>ISSN: 0902-0063</identifier><identifier>EISSN: 1399-0012</identifier><identifier>DOI: 10.1111/ctr.13281</identifier><identifier>PMID: 29754418</identifier><language>eng</language><publisher>Denmark</publisher><subject>alloantibody ; chronic ; lung (allograft) function/dysfunction ; quality of life ; rejection ; retransplantation</subject><ispartof>Clinical transplantation, 2018-06, Vol.32 (6), p.e13281-n/a</ispartof><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3251-378a91d3c4674a95df9a7e9706aa45e201f165e8e58a795dc17314cb7f154eb03</citedby><cites>FETCH-LOGICAL-c3251-378a91d3c4674a95df9a7e9706aa45e201f165e8e58a795dc17314cb7f154eb03</cites><orcidid>0000-0002-2693-8676 ; 0000-0002-5615-6974</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fctr.13281$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fctr.13281$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29754418$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Halloran, Kieran</creatorcontrib><creatorcontrib>Aversa, Meghan</creatorcontrib><creatorcontrib>Tinckam, Kathryn</creatorcontrib><creatorcontrib>Martinu, Tereza</creatorcontrib><creatorcontrib>Binnie, Matthew</creatorcontrib><creatorcontrib>Chaparro, Cecilia</creatorcontrib><creatorcontrib>Chow, Chung‐Wai</creatorcontrib><creatorcontrib>Waddell, Tom</creatorcontrib><creatorcontrib>McRae, Karen</creatorcontrib><creatorcontrib>Pierre, Andrew</creatorcontrib><creatorcontrib>Perrot, Marc</creatorcontrib><creatorcontrib>Yasufuku, Kazuhiro</creatorcontrib><creatorcontrib>Cypel, Marcelo</creatorcontrib><creatorcontrib>Keshavjee, Shaf</creatorcontrib><creatorcontrib>Singer, Lianne G.</creatorcontrib><title>Comprehensive outcomes after lung retransplantation: A single‐center review</title><title>Clinical transplantation</title><addtitle>Clin Transplant</addtitle><description>Introduction
Lung retransplantation is an important therapy for a growing population of lung transplant recipients with graft failure, but detailed outcome data are lacking.
Methods
We conducted a retrospective cohort study of adult lung retransplant in the Toronto Lung Transplant Program from 2001 to 2013 (n = 38). We analyzed the postoperative course, graft function, renal function, microbiology, donor‐specific antibodies (DSA), quality of life, and survival compared to a control cohort of primary transplant recipients matched for age and era.
Results
Indication for retransplant was chronic lung allograft dysfunction in most retransplant recipients (35/38, 92%). The postoperative course was more complex after retransplant than primary (ventilation time, 8 vs 2 days, P < .01; ICU stay 14 vs 4 days, P < 0.01), and peak lung function was lower (FEV1 2.2L vs 3L, P < .01). Quality of life scores were comparable, as were renal function, microbiology, and donor‐specific antibody formation. Median survival was 1988 days after primary and 1475 days after retransplant (P = .39).
Conclusions
Lung retransplantation is associated with a more complex postoperative course and lower peak lung function, but the long‐term medical profile is similar to primary transplant. Lung retransplantation can be beneficial for carefully selected candidates with allograft failure.</description><subject>alloantibody</subject><subject>chronic</subject><subject>lung (allograft) function/dysfunction</subject><subject>quality of life</subject><subject>rejection</subject><subject>retransplantation</subject><issn>0902-0063</issn><issn>1399-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kEtOwzAQhi0EoqWw4AIoS1iktePYjtlVES-pCAmVteW6kxKUF3bSqjuOwBk5CS4p7JjNjGY-fRr9CJ0TPCa-Jqa1Y0KjhBygIaFShhiT6BANscSRnzkdoBPn3vyWE86O0SCSgsUxSYboMa3LxsIrVC5fQ1B3ralLcIHOWrBB0VWrwEJrdeWaQletbvO6ug6mgcurVQFfH58Gqh1pYZ3D5hQdZbpwcLbvI_RyezNP78PZ091DOp2FhkaMhFQkWpIlNTEXsZZsmUktQArMtY4ZRJhk_k9IgCVa-LMhgpLYLERGWAwLTEfosvc2tn7vwLWqzJ2Bwr8IdedUhGkiMOOcefSqR42tnbOQqcbmpbZbRbDapad8euonPc9e7LXdooTlH_kblwcmPbDJC9j-b1Lp_LlXfgODhnpI</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Halloran, Kieran</creator><creator>Aversa, Meghan</creator><creator>Tinckam, Kathryn</creator><creator>Martinu, Tereza</creator><creator>Binnie, Matthew</creator><creator>Chaparro, Cecilia</creator><creator>Chow, Chung‐Wai</creator><creator>Waddell, Tom</creator><creator>McRae, Karen</creator><creator>Pierre, Andrew</creator><creator>Perrot, Marc</creator><creator>Yasufuku, Kazuhiro</creator><creator>Cypel, Marcelo</creator><creator>Keshavjee, Shaf</creator><creator>Singer, Lianne G.</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2693-8676</orcidid><orcidid>https://orcid.org/0000-0002-5615-6974</orcidid></search><sort><creationdate>201806</creationdate><title>Comprehensive outcomes after lung retransplantation: A single‐center review</title><author>Halloran, Kieran ; Aversa, Meghan ; Tinckam, Kathryn ; Martinu, Tereza ; Binnie, Matthew ; Chaparro, Cecilia ; Chow, Chung‐Wai ; Waddell, Tom ; McRae, Karen ; Pierre, Andrew ; Perrot, Marc ; Yasufuku, Kazuhiro ; Cypel, Marcelo ; Keshavjee, Shaf ; Singer, Lianne G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3251-378a91d3c4674a95df9a7e9706aa45e201f165e8e58a795dc17314cb7f154eb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>alloantibody</topic><topic>chronic</topic><topic>lung (allograft) function/dysfunction</topic><topic>quality of life</topic><topic>rejection</topic><topic>retransplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Halloran, Kieran</creatorcontrib><creatorcontrib>Aversa, Meghan</creatorcontrib><creatorcontrib>Tinckam, Kathryn</creatorcontrib><creatorcontrib>Martinu, Tereza</creatorcontrib><creatorcontrib>Binnie, Matthew</creatorcontrib><creatorcontrib>Chaparro, Cecilia</creatorcontrib><creatorcontrib>Chow, Chung‐Wai</creatorcontrib><creatorcontrib>Waddell, Tom</creatorcontrib><creatorcontrib>McRae, Karen</creatorcontrib><creatorcontrib>Pierre, Andrew</creatorcontrib><creatorcontrib>Perrot, Marc</creatorcontrib><creatorcontrib>Yasufuku, Kazuhiro</creatorcontrib><creatorcontrib>Cypel, Marcelo</creatorcontrib><creatorcontrib>Keshavjee, Shaf</creatorcontrib><creatorcontrib>Singer, Lianne G.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Halloran, Kieran</au><au>Aversa, Meghan</au><au>Tinckam, Kathryn</au><au>Martinu, Tereza</au><au>Binnie, Matthew</au><au>Chaparro, Cecilia</au><au>Chow, Chung‐Wai</au><au>Waddell, Tom</au><au>McRae, Karen</au><au>Pierre, Andrew</au><au>Perrot, Marc</au><au>Yasufuku, Kazuhiro</au><au>Cypel, Marcelo</au><au>Keshavjee, Shaf</au><au>Singer, Lianne G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comprehensive outcomes after lung retransplantation: A single‐center review</atitle><jtitle>Clinical transplantation</jtitle><addtitle>Clin Transplant</addtitle><date>2018-06</date><risdate>2018</risdate><volume>32</volume><issue>6</issue><spage>e13281</spage><epage>n/a</epage><pages>e13281-n/a</pages><issn>0902-0063</issn><eissn>1399-0012</eissn><abstract>Introduction
Lung retransplantation is an important therapy for a growing population of lung transplant recipients with graft failure, but detailed outcome data are lacking.
Methods
We conducted a retrospective cohort study of adult lung retransplant in the Toronto Lung Transplant Program from 2001 to 2013 (n = 38). We analyzed the postoperative course, graft function, renal function, microbiology, donor‐specific antibodies (DSA), quality of life, and survival compared to a control cohort of primary transplant recipients matched for age and era.
Results
Indication for retransplant was chronic lung allograft dysfunction in most retransplant recipients (35/38, 92%). The postoperative course was more complex after retransplant than primary (ventilation time, 8 vs 2 days, P < .01; ICU stay 14 vs 4 days, P < 0.01), and peak lung function was lower (FEV1 2.2L vs 3L, P < .01). Quality of life scores were comparable, as were renal function, microbiology, and donor‐specific antibody formation. Median survival was 1988 days after primary and 1475 days after retransplant (P = .39).
Conclusions
Lung retransplantation is associated with a more complex postoperative course and lower peak lung function, but the long‐term medical profile is similar to primary transplant. Lung retransplantation can be beneficial for carefully selected candidates with allograft failure.</abstract><cop>Denmark</cop><pmid>29754418</pmid><doi>10.1111/ctr.13281</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2693-8676</orcidid><orcidid>https://orcid.org/0000-0002-5615-6974</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-0063 |
| ispartof | Clinical transplantation, 2018-06, Vol.32 (6), p.e13281-n/a |
| issn | 0902-0063 1399-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2038705665 |
| source | Access via Wiley Online Library |
| subjects | alloantibody chronic lung (allograft) function/dysfunction quality of life rejection retransplantation |
| title | Comprehensive outcomes after lung retransplantation: A single‐center review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A09%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comprehensive%20outcomes%20after%20lung%20retransplantation:%20A%20single%E2%80%90center%20review&rft.jtitle=Clinical%20transplantation&rft.au=Halloran,%20Kieran&rft.date=2018-06&rft.volume=32&rft.issue=6&rft.spage=e13281&rft.epage=n/a&rft.pages=e13281-n/a&rft.issn=0902-0063&rft.eissn=1399-0012&rft_id=info:doi/10.1111/ctr.13281&rft_dat=%3Cproquest_cross%3E2038705665%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2038705665&rft_id=info:pmid/29754418&rfr_iscdi=true |